Pharmicell said its sales in the third quarter of this year rose 75.7% from a year earlier to 25.6 billion won, while operating profit jumped 533.9% to 8.1 billion won.
Cumulative sales for January–September this year were 79.4 billion won, with operating profit of 24.6 billion won. Those figures were up 83.1% and 1,531.1%, respectively, from a year earlier.
By business division, the Biochemical Division posted 77.5 billion won in sales, and the Biomedical Division recorded 1.9 billion won.
In particular, sales of low-dielectric-constant electronic materials in the Biochemical Division rose 181.7% from a year earlier to 43.2 billion won, accounting for 54% of total sales and driving high growth. The company said steady demand driven by the growth of the artificial intelligence (AI) industry supported the sales momentum.
Over the same period, sales of active pharmaceutical ingredients were 15.4 billion won, up 65.5%. The company said the expansion of global supply to overseas clients led to higher sales.
A Pharmicell official said, "With the expansion of the AI industry, demand for low-dielectric-constant materials is increasing and global supplies of active pharmaceutical ingredients are also growing, so the growth trend continues in the second half," adding, "We will strengthen the competitiveness of our core businesses and expand into new markets."